Compare PGEN & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | PEB |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | N/A | 2009 |
| Metric | PGEN | PEB |
|---|---|---|
| Price | $4.16 | $12.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $7.67 | ★ $12.28 |
| AVG Volume (30 Days) | ★ 5.7M | 2.0M |
| Earning Date | 11-13-2025 | 02-25-2026 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $6,309,000.00 | ★ $1,464,126,000.00 |
| Revenue This Year | $342.78 | $2.18 |
| Revenue Next Year | $478.46 | $0.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 59.20 | 0.99 |
| 52 Week Low | $1.05 | $7.42 |
| 52 Week High | $5.23 | $14.21 |
| Indicator | PGEN | PEB |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 66.95 |
| Support Level | $4.39 | $11.48 |
| Resistance Level | $4.95 | $12.95 |
| Average True Range (ATR) | 0.31 | 0.40 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 22.06 | 64.14 |
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.